Reports, Positive Results, Updated Clinical Safety and Efficacy Data by Healthcare Companies - Research Report on Johnson & Johnson, Merck, BioMarin, Array BioPharma, and Brookdale Senior Living

NEW YORK, December 12, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Johnson & Johnson (NYSE: JNJ), Merck & Co. Inc. (NYSE: MRK), BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), Array BioPharma, Inc. (NASDAQ: ARRY), and Brookdale Senior Living Inc. (NYSE: BKD). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Johnson & Johnson Research Report

On December 8, 2013, Janssen Research & Development, LLC (Janssen), a part of Johnson & Johnson's Janssen Pharmaceutical Companies, reported positive results from a pivotal Phase 2 global registration study (MCD2001). According to the Company, siltuximab, which is an investigational compound, along with best supportive care (BSC), exhibited statistically significant efficacy and a tolerable safety profile compared with placebo and BSC in treating patients with the rare disorder Multicentric Castleman's Disease (MCD) who are HIV-negative and human herpes virus-8 (HHV-8)-negative. Commenting on the results, the lead study investigator Raymond S. Wong, MBChB, M.D., Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, stated, "MCD is a devastating disease that weakens the immune system and may lead to life-threatening infections." "These results are encouraging and from my perspective support the potential for siltuximab as a new treatment for these patients who previously had no approved treatment options." The Full Research Report on Johnson & Johnson - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/07a8_JNJ

--

Merck & Co. Inc. Research Report

On December 9, 2013, Merck & Co. Inc.'s (Merck) stock went up by 0.34%, closing the day at $49.56 per share. Over the past three trading days, the Company's stock went up by 0.51%, compared to the S&P 500 which also went up 0.87% during the same trading period. The Full Research Report on Merck & Co. Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/430d_MRK

--

BioMarin Pharmaceutical Inc. Research Report

On December 9, 2013, BioMarin Pharmaceutical Inc.'s (BioMarin) stock decreased by 0.23%, closing at $70.00 per share. For the previous three trading days, the Company's stock went down by 0.04%, compared to the Nasdaq composite which went up by 0.76% during the same trading period. The Full Research Report on BioMarin Pharmaceutical Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/9b6c_BMRN

--

Array BioPharma, Inc. Research Report

On December 9, 2013, Array BioPharma, Inc. (Array BioPharma) announced updated clinical safety and efficacy data on ARRY-614 in patients with myelodysplastic syndromes (MDS) at the 2013 Annual Meeting of the American Society of Hematology. Guillermo Garcia-Manero, M.D., Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, stated, "The emerging results from this study with ARRY-614 are very promising. ARRY-614 was generally well tolerated in these lower-risk MDS patients and I am particularly encouraged with the platelet effects observed in patients with thrombocytopenia, including platelet transfusion independence. Responses were seen in patients for whom hypomethylating agents had failed, a group with no available treatment options." Michael Needle, M.D., Chief Medical Officer, Array BioPharma, also added, "Significant unmet needs remain in the treatment of MDS. ARRY-614 is thought to operate at the progenitor cell level, distinct from currently available therapies, offering a unique mechanism of action for treatment of the cytopenias associated with MDS." The Full Research Report on Array BioPharma, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/e048_ARRY

--

Brookdale Senior Living Inc. Research Report

On December 9, 2013, Brookdale Senior Living Inc.'s (Brookdale Senior Living) stock reflected a 0.14% decrease, and closed the day at $28.14 per share. The Company's stock went down by 1.12% during the past three trading days, compared to the Dow Jones Industrial Average which went up by 0.85% over the same trading period. The Full Research Report on Brookdale Senior Living Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/fefe_BKD

----

EDITOR NOTES:

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
5. For any urgent concerns or inquiries, please contact us at [email protected].
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts' Corner